receptor antagonist (Ki
= 110 nM); inhibits S1P-induced Ca2+
release in HUVEC cells. Suppresses FTY-720-induced S1P3
receptor-mediated bradycardia in vivo
. Also inhibits S1P-induced breast cancer stem cell expansion in vitro
. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist.
Murakami et al.
Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation.
Hirata et al.
The citations listed below are publications that use Tocris products. Selected citations for TY 52156 include:
Showing Results 1 - 2 of 2